全文获取类型
收费全文 | 39220篇 |
免费 | 3271篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 318篇 |
儿科学 | 1201篇 |
妇产科学 | 1118篇 |
基础医学 | 5311篇 |
口腔科学 | 803篇 |
临床医学 | 4858篇 |
内科学 | 7062篇 |
皮肤病学 | 669篇 |
神经病学 | 3838篇 |
特种医学 | 1209篇 |
外科学 | 4481篇 |
综合类 | 814篇 |
一般理论 | 98篇 |
预防医学 | 5175篇 |
眼科学 | 455篇 |
药学 | 2376篇 |
1篇 | |
中国医学 | 33篇 |
肿瘤学 | 2728篇 |
出版年
2023年 | 336篇 |
2022年 | 230篇 |
2021年 | 1109篇 |
2020年 | 793篇 |
2019年 | 1213篇 |
2018年 | 1260篇 |
2017年 | 936篇 |
2016年 | 973篇 |
2015年 | 1031篇 |
2014年 | 1377篇 |
2013年 | 1945篇 |
2012年 | 2887篇 |
2011年 | 2819篇 |
2010年 | 1537篇 |
2009年 | 1286篇 |
2008年 | 2188篇 |
2007年 | 2121篇 |
2006年 | 2070篇 |
2005年 | 1957篇 |
2004年 | 1784篇 |
2003年 | 1560篇 |
2002年 | 1418篇 |
2001年 | 707篇 |
2000年 | 754篇 |
1999年 | 662篇 |
1998年 | 352篇 |
1997年 | 233篇 |
1996年 | 252篇 |
1995年 | 232篇 |
1994年 | 182篇 |
1993年 | 194篇 |
1992年 | 461篇 |
1991年 | 422篇 |
1990年 | 430篇 |
1989年 | 385篇 |
1988年 | 332篇 |
1987年 | 348篇 |
1986年 | 309篇 |
1985年 | 328篇 |
1984年 | 304篇 |
1983年 | 252篇 |
1982年 | 159篇 |
1981年 | 138篇 |
1980年 | 146篇 |
1979年 | 207篇 |
1978年 | 159篇 |
1975年 | 147篇 |
1974年 | 146篇 |
1973年 | 148篇 |
1972年 | 153篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
3.
Alexander D. Sherry MD Kelsey L. Corrigan MD MPH Ramez Kouzy MD Joseph Abi Jaoude MD Yumeng Yang MS Roshal R. Patel MD Douglas J. Totten MD MBA Neil B. Newman MD MS Prajnan Das MD MS MPH Cullen Taniguchi MD PhD Bruce Minsky MD Rebecca A. Snyder MD MPH C. David Fuller MD PhD Ethan Ludmir MD 《Cancer》2023,129(21):3430-3438
4.
5.
ChiaChi Lin TsaiSheng Yang ChiaJui Yen Rebecca Cheng Junjun Liu Chiun Hsu 《The oncologist》2020,25(12)
Lessons Learned
- The combination of ramucirumab (8 mg/kg intravenous, day 1 every 2 weeks) and FOLFOX4 as first‐line treatment in patients with advanced hepatocellular carcinoma (HCC) was not sufficiently tolerated.
- Preliminary efficacy data suggest that the combination may provide clinical benefit to patients with HCC.
- Dose modification and patient selection should be considered for the future development of ramucirumab plus FOLFOX chemotherapy for advanced HCC.
6.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
7.
Tiffany Li Hannah C. Timmins Tracy King Matthew C. Kiernan David Goldstein Susanna B. Park 《Hematological oncology》2020,38(3):229-243
Bortezomib-induced peripheral neuropathy (BIPN) is a common toxicity associated with the treatment of multiple myeloma (MM), typically requiring dose reduction, delay, or cessation of treatment protocol. This systematic review aimed to investigate risk factors, trends, and variability associated with the development of BIPN. Searches were undertaken using Medline, PubMed, Cochrane Central Register of Controlled Trials, Embase, Scopus, and Web of Science. Additional studies were identified by investigating authors' bibliographic references cited by original and review articles. Articles that reported on neuropathy in phase III randomised control trials involving bortezomib in any treatment arm for the treatment of MM were included in this review. A total of 43 full text articles met criteria, which examined 23 phase III trials (N = 8218). Overall incidence of neuropathy ranged from 8.4% to 80.5% (median = 37.8%) and severe neuropathy (grade 3-4) ranged from 1% to 33.2% (median = 8%). Similar reports of neuropathy of any grade and severe neuropathy were observed between the newly diagnosed and relapsed cohort. Bortezomib regimens with reduced dose intensity were associated with reduced neuropathy incidence. Increased cumulative dosing levels, intravenous compared with subcutaneous administration and combination therapy with thalidomide were associated with higher rates of BIPN. This analysis revealed that BIPN is a significant toxicity. More sensitive measures are required to capture the incidence and severity of BIPN. Better understanding of risk factors and reversibility profiles will minimise the number of cancer survivors living with residual treatment side effects. 相似文献
8.
An unprecedented mortality crisis befell the former socialist countries between 1989 and 1995, representing one of the greatest demographic shocks of the period after the Second World War. While it is likely that country‐level variation in the post‐socialist mortality crisis in Eastern Europe can be explained by a constellation of political and socio‐economic factors, no comprehensive review of the existing scholarly attempts at explaining these factors exists. We review 39 cross‐national multi‐variable peer reviewed studies of social determinants of mortality in post‐socialist Europe in order to assess the social factors behind the post‐socialist mortality crisis, determine the gaps in the existing literature and to make suggestions for future research. We propose a novel methodology to determine the relative importance of variables based on the ratio of significant to insignificant findings for each variable. The literature identifies inequality, welfare payments, religious composition, democracy, economic performance and unemployment as the leading factors that have a significant influence on mortality outcomes. Existing cross‐country studies fail to establish a definitive connection between mortality and diets, drinking patterns, liberalisation, trust, health expenditure and war. We also point out that the level of analysis is not a neutral methodological choice but might influence the results themselves. 相似文献
9.
Rebecca Carman Lesley Andrew Amanda Devine Jacques Oosthuizen 《Australian and New Zealand journal of public health》2019,43(6):563-569
Objective: To identify behavioural barriers of service provision within general practice that may be impacting the vaccination coverage rates of Aboriginal children in Perth, Western Australia (WA). Methods: A purposive developed survey was distributed to 316 general practices across Perth and three key informant interviews were conducted using a mixed‐methods approach. Results: Of the surveyed participants (n=101), 67.4% were unaware of the low vaccination coverage in Aboriginal children; 64.8% had not received cultural sensitivity training in their workplace and 46.8% reported having inadequate time to follow up overdue child vaccinations. Opportunistic vaccination was not routinely performed by 30.8% of participants. Key themes identified in the interviews were awareness, inclusion and cultural safety. Conclusion: Inadequate awareness of the current rates, in association with a lack of cultural safety training, follow‐up and opportunistic practice, may be preventing greater vaccination uptake in Aboriginal children in Perth. Cultural safety is a critical component of the acceptability and accessibility of services; lack of awareness may restrict the development of strategies designed to equitably address low coverage. Implications: The findings of this study provide an opportunity to raise awareness among clinicians in general practice and inform future strategies to equitably deliver targeted vaccination services to Aboriginal children. 相似文献
10.